Bendamustine Plus Rituximab May Be Safe, Effective for Lymphoma

Share this content:
Bendamustine plus rituximab safe in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin and mantle cell lymphomas.
Bendamustine plus rituximab safe in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin and mantle cell lymphomas.

Bendamustine plus rituximab is safe in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphomas and mantle cell lymphoma, and is effective for patients with relapsed/refractory indolent B-cell non-Hodgkin lymphomas, a recent study published online early in the International Journal of Hematology has shown.

For the phase II study, researchers sought to evaluate the efficacy and safety of bendamustine and rituximab in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Researchers enrolled 53 patients aged 20-79 years with pathologically confirmed B-cell non-Hodgkin lymphomas or mantle cell lymphomas. All patients were relapsed/refractory after receiving one to two rituximab-containing regimens.

RELATED: Conventional Karyotyping Rarely Positive in Lymphoma Staging

All patients received bendamustine 90mg/m2 IV for 2 consecutive days plus rituximab 375mg/m2 IV on day 1, 2, or 3, for up to four 4-week cycles.

Results showed that the best overall response rate was 94% and the complete response rate was 71%. Patients with follicular lymphoma had an overall response rate and complete response rate of 95% and 80%, respectively.

In regard to safety, grade 3-4 leukopenia and neutropenia occurred in 42% and 40% of patients, respectively.

Reference

  1. Matsumoto K, Takayama N, Aisa Y, et al. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol. 2015. [Epub ahead of print]. doi: 10.1007/s12185-015-1767-3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs